Oncologist
Ann-Lii Cheng, MD, PhD
Ann-Lii Cheng is distinguished professor and Director of the NTU Cancer Center of National Taiwan University. He received his MD degree, PhD degree, and his specialty training in internal medicine and medical oncology at the Medical School of the National Taiwan University. In 1990, he was a research fellow at the Comprehensive Cancer Center of the University of Wisconsin, Madison, USA. Dr. Cheng has been actively involved in basic and translational research in hepatocellular carcinoma and has published more than 300 peer reviewed articles.
He was elected as Fellow of American Association for the Advancement of Science (AAAS) in 2007. He received the national award of “outstanding contributions for science and technology” in 2008, and a most prestigious national award for academic excellence in 2010. He served as president of the Taiwan Oncology Society during 2009- 2011. He was elected as National Chair Professorship in 2013, and became the founding director of NTU Cancer Center since 2013.
He was elected as Fellow of American Association for the Advancement of Science (AAAS) in 2007. He received the national award of “outstanding contributions for science and technology” in 2008, and a most prestigious national award for academic excellence in 2010. He served as president of the Taiwan Oncology Society during 2009- 2011. He was elected as National Chair Professorship in 2013, and became the founding director of NTU Cancer Center since 2013.
Senior Clinical Advisor
Michael G. Kauffman, MD, PhD
Dr. Kauffman co-founded Karyopharm with Dr. Sharon Shacham in 2008 and served as our Chief Executive Officer from January 2011 to April 2021, as Chief Medical Officer from December 2012 to July 2019, and as a director since 2008. He is currently a Senior Clinical Advisor to the Company helping to guide additional clinical development for Karyopharm’s robust pipeline of programs, with an increasing focus on solid tumor indications.
Prior to joining Karyopharm, Dr. Kauffman served as Chief Medical Officer at Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. in November 2009 where he was Chief Medical Officer and where he led the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor which was approved by the FDA for the treatment of refractory myeloma in 2012.
Prior to joining Onyx, Dr. Kauffman was an operating partner at Bessemer Venture Partners where he led investments in biotechnology companies. Prior to that, he served as President and Chief Executive Officer at Epix Pharmaceuticals, Inc. and President and Chief Executive Officer of Predix Pharmaceuticals, Inc. Dr. Kauffman led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals in 2006, oversaw the discovery and development of four new clinical candidates, and led collaboration transactions with Amgen and GlaxoSmithKline.
From 2000 to 2002, Dr. Kauffman was Vice President, Clinical at Millennium Pharmaceuticals, Inc., where he led the Velcade® (bortezomib) development program. From 1997 to 2000, Dr. Kauffman served in senior leadership roles at Millennium Predictive Medicine, Inc., a subsidiary of Millennium Pharmaceuticals, where he led the discovery and development of novel molecular diagnostics for major cancers and led transactions with Becton-Dickenson and Bristol Myers Squibb. From 1995 to 1997, he held a number of senior positions at Biogen Idec, Inc., where he led the clinical development of anti-D40L antibodies in autoimmune and inflammatory diseases, and acted as the main medical advisor to the Biogen business development group.
Dr. Kauffman currently serves on the board of directors of Adicet Bio, Kezar Life Sciences, Inc. and Verastem Inc., which are all public biopharmaceutical companies.
Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College, his Doctor of Medicine and Doctor of Philosophy from Johns Hopkins Medical School, and trained in internal medicine and rheumatology at Beth Israel (now Beth Israel Deaconness Medical Center) and Massachusetts General Hospitals. He is board certified in internal medicine.
Prior to joining Karyopharm, Dr. Kauffman served as Chief Medical Officer at Onyx Pharmaceuticals Inc., which acquired Proteolix Inc. in November 2009 where he was Chief Medical Officer and where he led the development of Kyprolis® (carfilzomib), a novel proteasome inhibitor which was approved by the FDA for the treatment of refractory myeloma in 2012.
Prior to joining Onyx, Dr. Kauffman was an operating partner at Bessemer Venture Partners where he led investments in biotechnology companies. Prior to that, he served as President and Chief Executive Officer at Epix Pharmaceuticals, Inc. and President and Chief Executive Officer of Predix Pharmaceuticals, Inc. Dr. Kauffman led the merger of Predix Pharmaceuticals and Epix Pharmaceuticals in 2006, oversaw the discovery and development of four new clinical candidates, and led collaboration transactions with Amgen and GlaxoSmithKline.
From 2000 to 2002, Dr. Kauffman was Vice President, Clinical at Millennium Pharmaceuticals, Inc., where he led the Velcade® (bortezomib) development program. From 1997 to 2000, Dr. Kauffman served in senior leadership roles at Millennium Predictive Medicine, Inc., a subsidiary of Millennium Pharmaceuticals, where he led the discovery and development of novel molecular diagnostics for major cancers and led transactions with Becton-Dickenson and Bristol Myers Squibb. From 1995 to 1997, he held a number of senior positions at Biogen Idec, Inc., where he led the clinical development of anti-D40L antibodies in autoimmune and inflammatory diseases, and acted as the main medical advisor to the Biogen business development group.
Dr. Kauffman currently serves on the board of directors of Adicet Bio, Kezar Life Sciences, Inc. and Verastem Inc., which are all public biopharmaceutical companies.
Dr. Kauffman received his Bachelor of Arts in Biochemistry from Amherst College, his Doctor of Medicine and Doctor of Philosophy from Johns Hopkins Medical School, and trained in internal medicine and rheumatology at Beth Israel (now Beth Israel Deaconness Medical Center) and Massachusetts General Hospitals. He is board certified in internal medicine.
Oncologist
San-Chi Chen, MD
Dr. Chen is a clinician at the Department of Oncology, Taipei Veterans General Hospital. Dr. Chen has extensive experience in research and development of immunotherapies in solid tumors and has overseen numerous successful enrollment efforts in several major pivotal immunotherapy trials in liver cancer. Dr. Chen received his M.D. from Taipei Medical University.
Pharmacology & Regulatory Strategy
M. Sherry Ku, PhD
Dr. Sherry Ku is currently the Chairperson of Board and CEO of Savior Lifetec Corp. (2015 IPO in Taiwan). Previously she was the founding President and Board Member of RuenHuei Biopharmaceutical Company, and the founding President/CSO of TWi Biotech/TWi Pharma (Anchen Taiwan, 2012 IPO). Under her leadership, 6 High Barrier Abbreviated New Drug Applications (ANDAs), including 3 Paragraph IV, were filed within 18 months. Before her returning to Taiwan, Dr. Ku headed up the Pharmaceutical Development group in Wyeth Research USA (now Pfizer). Her responsibilities starts from discovery interface through clinical proof of concept. She oversees new drug development for over 170 new clinical leads, resulting in 85 original filings of New Molecular Entity (NME) Investigational New Drug (IND) and 8 commercial products including Suprax, Zosyn/Tazocin, Zebeta, Isovorin, Thioplex, Sonata, Tygacil and Bosutinib from pre-formulation through New Drug Application (NDA) and FDA’s pre-approval inspection (PAI) activities. Dr. Ku is a registered pharmacist and has a PhD degree in Pharmaceutics and Pharmaceutical Chemistry. She currently holds over 70 patents/invention disclosures and has 62 journal publications. She was the Vice Chair of NJ Pharmaceutical Discussion Group and is the chair elect of AAPS Physical Pharmacy and Biopharmaceutical section. She sits on USP expert council and consults for CFDA, TFDA, IPEC and various Quality Councils.
Bioengineering & Translational Research
Dr. Jun Ishihara, PhD
Dr. Jun Ishihara is a Lecturer (equivalent to Assistant Professor in the USA) in the Department of Bioengineering at Imperial College London. The Ishihara laboratory works in the field of protein engineering, with research foci in cancer immunotherapy, autoimmunity, and regenerative medicine.
Dr. Ishihara received his PhD in stem cell biology from the University of Tokyo. He then conducted postdoctoral training in the laboratory of Jeffrey Hubbell first at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland from 2014 to 2016 and then at the University of Chicago from 2016 to 2020 when the laboratory relocated to the Pritzker School of Molecular Engineering.
Dr. Ishihara has developed novel technologies in the field of immuno-engineering in order to improve current therapies and discover new drugs. He has developed novel approaches to cancer immunotherapy that achieve localised immune activation by targeting the tumour microenvironment. These methods make cancer immunotherapy safe and effective. Dr. Ishihara has also engineered treatments for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In the field of regenerative medicine, he has developed novel approaches to efficiently deliver growth factors to the wound site to promote wound healing.
Dr. Ishihara received his PhD in stem cell biology from the University of Tokyo. He then conducted postdoctoral training in the laboratory of Jeffrey Hubbell first at the Ecole Polytechnique Fédérale de Lausanne (EPFL) in Switzerland from 2014 to 2016 and then at the University of Chicago from 2016 to 2020 when the laboratory relocated to the Pritzker School of Molecular Engineering.
Dr. Ishihara has developed novel technologies in the field of immuno-engineering in order to improve current therapies and discover new drugs. He has developed novel approaches to cancer immunotherapy that achieve localised immune activation by targeting the tumour microenvironment. These methods make cancer immunotherapy safe and effective. Dr. Ishihara has also engineered treatments for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In the field of regenerative medicine, he has developed novel approaches to efficiently deliver growth factors to the wound site to promote wound healing.
Bioengineering & Translational Research
Min Yuan Chou, PhD
Min Yuan get his PhD degree from Tulan University. Min Yuan has established several core competences in developing recombinant protein technologies for both therapeutic and diagnostic applications in our protein engineering team. A unique non-antibody scaffold platform, Collabody, which utilizes a short triplex-forming collagen-like peptide (around 30 mers) to make multivalent protein binders has been developed and one drug candidate is currently in the late stage of non-clinical development. Other core technologies related to biotherapeutics have been developed, including: (1) mouse hybridomas for mAb screening using high-throughput Clonepix selection; (2) phage-display antibody fragments for fully-human mAb selection or affinity maturation; (3) structure-based design for murine IgG humanization, followed by structural optimization for process development; (4) stable mammalian cell line development for high-level production of IgG and Fab fragments; (5) cell line medium optimization; (6) upstream process development of IgG using disposal Wave Cellbag system; (7) downstream process development for protein purification; (8) bioconjugations, including nanoparticle-antibody and antibody-drug conjugates with freedom-to-operate linker toxin; and (9) analytical method development, including protein drug characterization, antibody pairing for developing PK studies, ADA method development, and cell-based bioassays.
Vice Chairman, Asia Pacific, PAREXEL
Albert Liou
With 7,000 employees in 25 locations across 12 countries in the region, PAREXEL now has more than a third of its global staff in Asia Pacific (APAC). Albert Liou, Vice Chairman, Asia Pacific, PAREXEL, provides insights into the company’s unique contribution to the R&D-driven ecosystem in Taiwan, where the global clinical research organization (CRO) also has its regional headquarters.
Albert Liou is now:
l Independent Board Director, SUNDIA MEDITECH GROUP
l Chairman, Fidelitas International Corp.
l Investment Board, Taiwania Capital
Albert Liou was clinical data analyst in Amgen Inc (Thousand Oaks) and The Liposom Company.
Albert Liou is now:
l Independent Board Director, SUNDIA MEDITECH GROUP
l Chairman, Fidelitas International Corp.
l Investment Board, Taiwania Capital
Albert Liou was clinical data analyst in Amgen Inc (Thousand Oaks) and The Liposom Company.
© Copyright | LIBO PHARMA CORP. | All rights reserved | Private Policy 2024